These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 20471942)
1. DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. Schlereth K; Beinoraviciute-Kellner R; Zeitlinger MK; Bretz AC; Sauer M; Charles JP; Vogiatzi F; Leich E; Samans B; Eilers M; Kisker C; Rosenwald A; Stiewe T Mol Cell; 2010 May; 38(3):356-68. PubMed ID: 20471942 [TBL] [Abstract][Full Text] [Related]
2. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Qian H; Wang T; Naumovski L; Lopez CD; Brachmann RK Oncogene; 2002 Nov; 21(51):7901-11. PubMed ID: 12420228 [TBL] [Abstract][Full Text] [Related]
3. Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Li J; Tan J; Zhuang L; Banerjee B; Yang X; Chau JF; Lee PL; Hande MP; Li B; Yu Q Cancer Res; 2007 Dec; 67(23):11317-26. PubMed ID: 18056458 [TBL] [Abstract][Full Text] [Related]
4. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Delia D; Goi K; Mizutani S; Yamada T; Aiello A; Fontanella E; Lamorte G; Iwata S; Ishioka C; Krajewski S; Reed JC; Pierotti MA Oncogene; 1997 May; 14(18):2137-47. PubMed ID: 9174049 [TBL] [Abstract][Full Text] [Related]
5. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Seoane J; Le HV; Massagué J Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701 [TBL] [Abstract][Full Text] [Related]
6. Comparative binding of p53 to its promoter and DNA recognition elements. Weinberg RL; Veprintsev DB; Bycroft M; Fersht AR J Mol Biol; 2005 May; 348(3):589-96. PubMed ID: 15826656 [TBL] [Abstract][Full Text] [Related]
7. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines. Crowe DL; Sinha UK Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195 [TBL] [Abstract][Full Text] [Related]
8. Role for Kruppel-like factor 4 in determining the outcome of p53 response to DNA damage. Zhou Q; Hong Y; Zhan Q; Shen Y; Liu Z Cancer Res; 2009 Nov; 69(21):8284-92. PubMed ID: 19826046 [TBL] [Abstract][Full Text] [Related]
9. Multiple response elements and differential p53 binding control Perp expression during apoptosis. Reczek EE; Flores ER; Tsay AS; Attardi LD; Jacks T Mol Cancer Res; 2003 Dec; 1(14):1048-57. PubMed ID: 14707288 [TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Huang Y; Tan M; Gosink M; Wang KK; Sun Y Cancer Res; 2002 May; 62(10):2913-22. PubMed ID: 12019172 [TBL] [Abstract][Full Text] [Related]
11. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Koutsodontis G; Vasilaki E; Chou WC; Papakosta P; Kardassis D Biochem J; 2005 Jul; 389(Pt 2):443-55. PubMed ID: 15790310 [TBL] [Abstract][Full Text] [Related]
12. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Liu X; Yue P; Khuri FR; Sun SY Cancer Res; 2005 Oct; 65(20):9169-75. PubMed ID: 16230375 [TBL] [Abstract][Full Text] [Related]
13. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Mirza A; Wu Q; Wang L; McClanahan T; Bishop WR; Gheyas F; Ding W; Hutchins B; Hockenberry T; Kirschmeier P; Greene JR; Liu S Oncogene; 2003 Jun; 22(23):3645-54. PubMed ID: 12789273 [TBL] [Abstract][Full Text] [Related]
14. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Takimoto R; El-Deiry WS Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207 [TBL] [Abstract][Full Text] [Related]
15. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971 [TBL] [Abstract][Full Text] [Related]
16. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function. Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999 [TBL] [Abstract][Full Text] [Related]
17. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705 [TBL] [Abstract][Full Text] [Related]
18. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death]. Mendoza-Rodríguez CA; Cerbón MA Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714 [TBL] [Abstract][Full Text] [Related]
19. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene. Schäfer H; Trauzold A; Sebens T; Deppert W; Fölsch UR; Schmidt WE Oncogene; 1998 May; 16(19):2479-87. PubMed ID: 9627114 [TBL] [Abstract][Full Text] [Related]
20. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage. Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]